On April 26, 2023, the FDA approved Vowst for the prevention of recurrence of Clostridioides (formerly known as Clostridium) difficile infection (CDI). [1] There are approximately 500,000 cases of CDI each year in the United States, leading to 10,000 – 15,000 deaths per year. It is the most common hospital acquired infection. Read more.